Replimune

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Replimune sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 5 currently recruiting early-phase tilt top decile by trial count

Replimune: 9 sponsored US clinical trials, 5 recruiting.

Replimune sponsors 9 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting. 1 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hepatocellular Carcinoma, with 2 trials.

Top-decile sponsor footprint

Replimune ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING

A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3

NCT06887348
RECRUITING Phase 2

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

NCT06581406
RECRUITING Phase 2

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

NCT05733598
RECRUITING Phase 3

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

NCT06264180
RECRUITING Phase 1

Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies

NCT04349436
ACTIVE NOT RECRUITING Phase 1

Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours

NCT04735978
ACTIVE NOT RECRUITING Phase 2

Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer

NCT04050436
ACTIVE NOT RECRUITING Phase 2

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

NCT03767348
TERMINATED Phase 2

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

NCT05733611

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 5
Phase 3 1

Therapeutic Areas

Hepatocellular Carcinoma 2
Advanced Solid Tumor 2
Microsatellite Instability-High (MSI-H) 1
Advanced Cutaneous Squamous Cell Carcinoma 1
Locally Advanced Cutaneous Squamous Cell Carcinoma 1
Non-melanoma Skin Cancer (NMSC) 1
Metastatic Uveal Melanoma 1
Advanced Melanoma 1
Metastatic Cutaneous Squamous Cell Carcinoma 1
Merkel Cell Carcinoma 1

What is open in the Replimune pipeline

5 recruiting of 9 indexed (56% open).

Phase mix: 1 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Hepatocellular Carcinoma (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Replimune: open-pipeline peers nationwide

Peers matched on 9 registered trials and 56% open enrollment, not the therapeutic-area sidebar.

Replimune sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 81012141618 0%20%40%60% Total trials Recruiting share Replimune4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyDisc MedicineHeart Rhythm Clinical and Research SolutionsJoseph TuscanoMGH Institute of Health Professions
Replimune sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Replimune sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 56% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Replimune page

9 registered trials is a research-attention snapshot, not an endorsement of Replimune or any single study.

  • 5 of Replimune's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Hepatocellular Carcinoma is the condition Replimune studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hepatocellular Carcinoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Replimune pipeline card: 9 registered trials from official public datasets.Report a data error.